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a b s t r a c t
Peripheral neuropathy is a severe dose limiting toxicity associated with cancer chemotherapy. Ever since
it was identiﬁed, the clear pathological mechanisms underlying chemotherapy induced peripheral
neuropathy (CIPN) remain sparse and considerable involvement of oxidative stress and neuroinﬂamma-
tion has been realized recently. Despite the empirical use of antioxidants in the therapy of CIPN, the
oxidative stress mediated neuronal damage in peripheral neuropathy is still debatable. The current
review focuses on nerve damage due to oxidative stress and mitochondrial dysfunction as key
pathogenic mechanisms involved in CIPN. Oxidative stress as a central mediator of apoptosis, neuroin-
ﬂammation, metabolic disturbances and bioenergetic failure in neurons has been highlighted in this
review along with a summary of research on dietary antioxidants and other nutraceuticals which have
undergone prospective controlled clinical trials in patients undergoing chemotherapy.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
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Introduction
Chemotherapy induced peripheral neuropathy (CIPN) remains
one of the major limitations in oncology clinics due to increasing
number of cancer patients, lack of effective treatment strategy,
relapse of disease [1]. Around 30–40% of patients undergoing
chemotherapy develop peripheral neuropathy and experience
symptoms of pain and sensory disturbances [2]. According to
National Cancer Institute (NCI), CIPN is one of the major reasons
responsible for cessation of treatment, and hence is responsible for
decreased chemotherapeutic efﬁcacy and higher relapses [3].
Symptoms of peripheral nerve damage range from sensorimotor
deﬁcits (tingling sensation, burning pain in the arms, allodynia
and hyperalgesia) to various functional deﬁcits (impaired axonal
transmission and reduced nutritive blood ﬂow to nerves [4]). The
most frequent agents causing CIPN are platinum compounds,
taxane derivatives, vinca alkaloids, epothilones, thalidomide and
bortezomib, which adversely affect the peripheral nervous system
through dissimilar mechanisms summarized in Fig. 1 [5].
Although, the molecular pathomechanism and severity may vary
with the inducing agent, physical damage to the neurons by
chemotherapeutic agent is a common mechanism underlying
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the disease pathology [4]. The physical damage by chemothera-
peutic drugs leads to functional impairment in neurons through
oxidative stress, inﬂammation, apoptosis and electrophysiological
disturbances. The scope of the present review is to present a basic
idea on the possible role of oxidative stress and related pathome-
chanisms in CIPN based upon the existing experimental evidences.
Susceptibility of peripheral nervous system (PNS) to oxidative stress
It is a recognized fact that antineoplastic agents produce
reactive oxygen species (ROS) to induce apoptosis in cancer cells
[6]. However, ROS generated during chemotherapy may interfere
with the normal cells and tissues and may be associated with the
various toxic events like cardio toxicity, nephrotoxicity, neurotoxi-
city, etc. Certain structural and functional attributes of peripheral
nervous system (PNS) make it more susceptible for accumulation
of chemotherapeutics and some neurotoxins (Fig. 2) [5]. Lack of an
efﬁcient vascular barrier and absence of lymph drainage make the
PNS more prone to toxic chemical insults. In addition mammalian
nerves are known to be more susceptible to oxidative stress
because of their high content of phospholipids, mitochondria rich
axoplasm and also due to weak cellular antioxidant defences [7]. It
has also been recently observed that structural and functional
impairment caused by anti-cancer drugs enhances mitochondrial
free radical production. Oxidative stress generated in this regard
causes physical damage to neurons by demyelination, mitochon-
drial dysfunction, microtubular damage and apoptosis [8].
Role of oxidative stress in the neuronal damage and incidence of
neuropathic pain
Although neurotoxicity caused by different classes of che-
motherapeutic drugs differs to a signiﬁcant extent, peripheral
neuronal degeneration or small ﬁber neuropathy remains the
end result of all CIPNs. It is been suspected that this might occur
by a common mechanism i.e. increased neuronal oxidative stress
as presented in Fig. 3. In fact, oxidative stress is identiﬁed to be
responsible for the neuronal damage in different models of
neuropathies such as diabetic neuropathy, acrylamide induced
neuropathy and Charcot–Marie neuropathy [9–12]. These observa-
tions laid the foundation for investigating possible involvement of
oxidative stress in CIPN. Chemotherapy induced mitochondrial
Fig. 1. Pathobiology of peripheral neuropathy induced by several chemotherapeutic agents: peripheral nerve damage associated with taxanes, vinca alkaloids and
bortezomib is characterized by various mechanisms like microtubular damage, mitochondrial dysfunction, neuronal apoptosis etc. [24]. Damage to the microtubules causes
impairment in axonal transmission and mitochondrial dysfunction. The mitochondrial dysfunction is due to opening of mitochondrial permeability transition pore (mPTP),
swollen and vacuolated mitochondria which brings Ca2þ deregulation and activation of caspases thus driving the neuronal cell towards apoptosis [34]. These changes
consequently stimulate microglia cells which releases the proinﬂammatory mediators and growth factors to the damaged areas leading to peripheral sensitization thus
causing spontaneous discharge and hyper excitability [3]. Further proinﬂammatory mediators are also capable of damaging myelin sheath [35]. Platinum compounds like
cisplatin and oxaliplatin can affect mitochondrial DNA, leading to mitochondrial dysfunction and also induces neuronal apoptosis through activation of mitogen activated
protein kinase (MAPK) pathway. These chemotherapeutic agents are also reported to cause peripheral sensitization by the up regulation of N-methyl D-aspartate (NMDA)
receptors, transient receptor potential vanilloid (TRPV) channels, and protein kinase C (PKC) [34].Oxaliplatin also alters the Naþ channel conductance through chelation of
Ca2þ [36]. All these effects can damage the sensory neurons such as Aδ and C ﬁbers, which leads to neuropathic pain characterized by hyperalgesia and allodynia.
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dysfunction and corresponding oxidative stress generation med-
iate the peripheral nerve damage. Oxidative stress mediated
neurodegeneration can execute through bioenergetic failure,
depletion of antioxidant defences, bio molecular damage, micro-
tubular disruption, ion channel activation, demyelination, neuroin-
ﬂammation, mitophagy impairment and neuronal death through
apoptosis [13–15]. The redox imbalance produced in neuronal cells
can be pharmacologically modulated through adjustment of
nuclear erythroid factor-2 related factor and nuclear factor kappa
light chain enhancer of B cells balance (Nrf2–NF-κB axis), and
hence these modulators have been tested for their efﬁcacy in
animal models of peripheral neuropathy [16,17]. An attempt has
been made to test peroxynitrite scavengers, PARP inhibitors in
animal models of CIPN, based on previous reports of their
beneﬁcial effect in diabetic neuropathy [18,19]. Attenuation of
symptoms of CIPN by the usage of peroxynitrite scavengers and
PARP inhibitors further supports a role of nitrosative–oxidative
stress in CIPN [15,20].
Mitochondrion: an emerging target in CIPN
Several prospective experimental studies in animal models
suggested that mitochondrial dysfunction is associated with che-
motherapy and axonal mitotoxicity contributes to neuropathic
symptoms produced by various chemotherapeutic agents such as
taxanes, vinca alkaloids, platinum compounds and bortezomib
[21–25]. In fact histological and microscopic observation of per-
ipheral nerve sections of chemotherapeutic drug treated animals
showed swollen and vacuolated mitochondria. These features
indicate neuronal apoptosis that may be through pathways like
caspase activation and Ca2þ dysregulation. Paclitaxel induced
apoptosis is mainly due to cytochrome c (Cyt c) release and Ca2þ
dysregulation through the opening of mPTP of mitochondria
[26,27]. Frataxin deﬁciency, mt DNA damage, formation of defec-
tive electron transport chain (etc) components and loss in anti-
oxidant defense enzymes has been demonstrated as mechanism
for platinum compounds induced neuropathy [27]. Accumulation
of dysfunctional mitochondria due to inefﬁcient mitophagy further
increases the free radical leakiness and this vicious cycle of
oxidative damage to the bio molecules and mitochondria provides
a feed-forward mechanism, that leads to further accumulation of
ROS and RNS in the neurons during the development and
progression of CIPN (Fig. 4). These experimental evidences clearly
indicate that oxidative stress induced mitochondrial dysfunction is
a central mediator of redox imbalance, apoptotic, autophagic and
bioenergetic failure in peripheral neurons. It has also been widely
observed that accumulation of oxidant damaged proteins and
organelles due to inefﬁcient autophagic pathway might be respon-
sible for neurodegeneration, and hence therapeutic alleviation of
Autophagy/Mitophagy is an unexplored potential target in periph-
eral neuropathies associated with nerve damage [28].
Oxidative stress in CIPN: biomarkers and therapeutic strategies
Experimental evidences support the involvement of mitochon-
dria mediated oxidative, nitrosative stress in development of
peripheral nerve damage. Identiﬁcation of these mechanisms
might be helpful in identifying newer biomarkers for the CIPN
and thus increases the chances of getting improved therapeutic
strategies. Currently diagnosis is based mainly on clinical exam-
ination and electrophysiological changes to monitor CIPN, hence
identiﬁcation of newer disease pathomechanisms will be helpful
in identifying new candidate biomarkers through which disease
progression can be identiﬁed at an earlier stage [3]. Oxidative
damage to peripheral neurons can cause damage to myelin sheath,
mitochondrial proteins and other antioxidant enzymes. Hence,
Fig. 2. Susceptibility of peripheral nervous system (PNS) to chemotherapeutic insult and oxidative stress: structural architecture of peripheral sensory and motor neurons
makes them more susceptible to drug induced nervous damage [5]. Dorsal root ganglion lacks an efﬁcient vascular barrier and hence, drugs like chemotherapeutics and
other neurotoxins can gain easy access to cell bodies of the sensory neurons. Unlike the central nervous system, the PNS doesn0t have an analogy of blood brain barrier, and
hence allows contact with some dangerous drug molecules, toxins and other blood proteins. Further, the absence of lymphatic system and cerebrospinal ﬂuid around the
peripheral nerves makes the potential dangerous substances to accumulate in the extracellular matrix around nervous tissue, which exacerbates the neuropathic damage
[37]. Chemotherapeutics accumulate in this manner can cause oxidative stress in the neurons directly by forming DNA adducts or indirectly by mitochondrial impairment of
electron transport chain [24]. Oxidative stress generated can cause nerve damage through microtubular disruption and or demyelination [14].
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identiﬁcation of levels of malondialdehyde, glutathione (GSH),
superoxide dismutase (SOD) and activities of mitochondrial
enzymes such as citrate synthase and ATP synthase can be helpful
in monitoring the course of peripheral neuropathy and response of
neuropathy to the treatment.
Due to the wide range of safety and tolerability, some of the
dietary antioxidants and nutraceuticals have been tested for their
clinical efﬁcacy against chemotherapy induced peripheral neuro-
pathy in large scale controlled clinical trials (Table 1). These agents
were reported to have clinical utility by their protective action on
neurons and they were found to alleviate functional disturbances
of neurons by improving the mitochondrial function and physiol-
ogy as shown in Fig. 5 [29,30].
Despite their wide usage and clinical efﬁcacy, the available
antioxidants present so far could only provide mild to moderate
pain relief in peripheral neuropathy [31]. Failure of antioxidants in
clinical trials might be due to their inability to reverse established
oxidative damage, radical speciﬁcity and interference with phy-
siological redox signaling pathways [28]. Targeted delivery of
antioxidants and employing the mechanism based approach,
clinical pathology and concentration dependent dosage schedule
in antioxidant trials will help us to develop better understanding
and might help us in devising newer strategies in CIPN [32].
Another possible explanation of translational failures of these
trials are the common toxicity criteria (CTC) assessment scales
used in CIPN trials, which should be remodiﬁed to include
necessary parametric measures, that will ensure accurate quanti-
ﬁcation of the drug induced effect [33].
Summary
This review highlighted the possible involvement of oxidative
stress as a vital pathogenic mechanism of CIPN. Molecular insight
into oxidant induced neuronal damage can probe a chance of
getting an alternative therapy for CIPN in the form of natural phyto
antioxidants or synthetic radical traps. Further, identiﬁcation of
antioxidant molecules having pleiotropic activity on other patho-
physiological pathways involved in the CIPN could aid in the
development of improved therapies. Since mitochondria are found
to be a primary source of cellular ROS, pharmacological interven-
tions targeted at maintenance of mitochondrial health and func-
tion is an alternative therapeutic approach for CIPN over direct
scavengers of free radicals for the treatment of CIPN.
Fig. 3. Role of oxidative stress in chemotherapy induced peripheral neuropathy (CIPN): the chemotherapeutic agents can form mitochondria DNA adducts and brings defects
in electron transport chain proteins leading to mitochondrial dysfunction [13]. This is accompanied with an imbalance in the intracellular redox potential and elevation of
reactive oxygen species especially superoxide. These major reactive species can elicit various alterations in peripheral neurons like redundant mitochondrial damage leading
to apoptosis, inﬂammation and ﬁnally neurodegeneration. These reactive species are also reported to cause damage to bio molecules like phospholipids that result in
demyelination, oxidation of proteins, releasing carbonyl bye products which can sensitize TRPV channels, inactivate antioxidant enzymes, and damage microtubules [14].
Nuclear DNA adducts and peroxynitrite creates strand breaks therefore activates PARP and p53, which forces the neuronal cell towards apoptosis [15]. Intracellular oxidative
stress can also cause peripheral nociceptor sensitization by elevating the levels of proinﬂammatory mediators [3]. All these metabolic, bioenergetic and functional deﬁcits in
neuron lead to the development of peripheral neuropathic damage.
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Fig. 4. Mitochondrial dysfunction in CIPN and role of its pharmacological modulation: the common factors associated with oxidative stress induced mitochondrial
dysfunction are disruption of calcium homeostasis, increased mitochondrial outer membrane permeability (MOMP), defective mitochondrial ATP synthesis, alteration in the
mitochondrial membrane potential (↓ΔΨm), induction of mPTP, release of Cyt c (since it loose its binding ability by oxidative induced damage to the cardiolipin),
mitochondrial swelling etc. [26]. All these steps occur together or one orchestrates with other and forms a vicious cycle which further disrupts mitochondrial function. This
ﬁnally leads to the cell death via apoptosis or necrosis. Pharmacological manipulation of mitochondrial toxicity with mitochondria-targeted antioxidants could help us to get
the better therapeutic outcome in CIPN through alleviation of mitochondria mediated oxidative stress [20,27,38].
Table 1
List of clinical studies conducted using nutraceuticals and dietary antioxidants in patients suffering from CIPN.
S.no. Model used Treatment schedule Parameters evaluated Results observed References
1. Paclitaxel/ cisplatin induced
neuropathy in patients
N-acetyl carnitine oral (1 g t.i.d
for 8 consecutive weeks)
Neurological examination, total
neuropathic score (TNS) and
quantitative sensory testing were
measured.
Improvement in TNS,
sensory symptoms and
neurophysiology were
observed in N-acetyl
carnitine treated patients.
[29]
2. Cisplatin/ docetaxel induced
neuropathy in patients
α-lipoic acid 600 mg i.v. once a
week for 3–5 weeks followed
by 1800 mg td p.o upto
6 months
Neurological examinations and
WHO toxicity score assessment
were evaluated
Improvement in
neurological symptoms
after treatment with
α-lipoic acid.
[30]
3. Cisplatin induced neurotoxicity
in women.
Glutathione (3 mg/m2) i.v
every 3 weeks for six courses.
A questionnaire on the subjective
symptoms of peripheral
neuropathy and quality of life was
assessed.
Decreased incidence of
CINP in glutathione treated
arm.
[39]
Oxaliplatin induced
neuropathy in patients
GSH (1500 mg/m2 over a
15-min infusion period before
oxaliplatin)
Electrophysiological parameters
and assessment of neurological
symptoms
Increased sural sensory
nerve conduction velocity
observed in GSH treated
patients
[40]
4. Paclitaxel/ docetaxel induced
neuropathy in patients
Melatonin 21 mg daily at
bedtime
Neurological examinations, toxicity
assessment as per NCI-CTC
3.0 scale and FACT-Taxane quality
of life questionnaire were
evaluated.
FACT-Taxane quality of life
end of study score was 137.
Reduced incidence of
neuropathy was observed
in melatonin treated
patients.
[41]
5. Oxaliplatin induced
neuropathy in patients
Oral N-acetyl cysteine
(1200 mg) (arm A) or placebo
(arm B).
Electrophysiological parameters
and assessment of neurological
symptoms.
Improved NCV (nerve
conduction velocity),
CMAP (compound muscle
action potential) and
decreased SAP (sensory
amplitude potential) were
observed after N-acetyl
cysteine treatment.
[42]
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Table 1 (continued )
S.no. Model used Treatment schedule Parameters evaluated Results observed References
6. Paclitaxel induced peripheral
neuropathy in patients
ω-3 fatty acids 640 mg t.i.d
orally/placebo
Electrophysiological parameters
and assessment of neurological
symptoms.
Reduced total sensory
neuropathy score,
improved NCV after
treatment with ω-3 fatty
acids.
[43]
7. Oxaliplatin induced
neuropathy in patients
Glutamine (15 g twice a day
orally for seven consecutive
days every 2 weeks starting on
the day of oxaliplatin infusion)
Electrophysiological parameters
and neurological symptoms were
assessed
Lower percentage of grade
1–2 peripheral neuropathy
after 2 cycles and lower
incidence of grade 3,
4 neuropathy after 4–6
cycles of glutamine
administration was
observed.
[44]
8. Taxanes, platinum compounds
and combination drug induced
neuropathy in patients.
Twice daily dosing of vitamin E
(400 mg)/ placebo.
The outcome was evaluated using
the common terminology criteria
for adverse events (CTCAE v 3.0)
and A questionnaire on the
subjective symptoms of peripheral
neuropathy.
Signiﬁcant difference in
the incidence of sensory
neuropathy between the
two arms was not
observed.
[46]
Vitamin E did not appear
to reduce the incidence
of sensory neuropathy.
Cisplatin induced neurotoxicity
in patients
vitamin E (300/day
mg/placebo)
The outcome was evaluated by
measuring total neuropathic score
(TNS) and quantitative sensory
testing
Vitamin E reduced the
incidence of sensory
neuropathy
[47,48]
Fig. 5. Role of nutraceutical antioxidants in the treatment of chemotherapy induced peripheral neuropathy (CIPN): nutraceutical antioxidants exhibited signiﬁcant
neuroprotection towards chemotherapy induced neurotoxicity by decreasing cellular oxidative stress through their inherent free radical scavenging property (glutathione
[39,40], melatonin [41], n-acetyl cysteine [42], ω-3 fatty acids [43], α-lipoic acid [30] etc) and indirectly by increasing whole blood concentrations of antioxidant enzymes
(glutamine [44], n-acetyl cysteine [42]), normalizing mitochondrial functions (n-acetyl carnitine [29], α-lipoic acid [30]), attenuating the production of proinﬂammatory
mediators (ω-3 fatty acids [43]) etc. Totally these nutraceutical antioxidants normalize the cellular functions, rescue mitochondrial impairment, inhibit neuronal
inﬂammation, apoptosis and therefore diminish the sensory nerve degeneration [2,45].
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